Osimertinib is a third‐generation EGFR TKI that was initially approved in November 2015 in the US for the treatment of patients with T790M‐positive NSCLC, following disease progression on 1L EGFR TKIs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.